ORKA Stock Price | Oruka Therapeutics, Inc. P/E, Revenue, EPS, & Forecasts

Oruka Therapeutics, Inc. • ORKA

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Oruka Therapeutics, Inc.

Ticker

ORKA

Trading on

NASDAQ

ISIN

US6876041087

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Lawrence Otto Klein Ph.D.

Headquarters

855 Oak Grove Avenue, Menlo Park, CA, United States, 94025

Employees

Website

https://orukatx.com

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Metrics

BasicAdvanced

Market cap

$1.28B

P/E ratio

EPS

$0.00

Dividend Yield

0.00%

Beta

Forward P/E ratio

EBIDTA

$-125M

Ex dividend date

Price & volume

Market cap

$1.28B

Average daily volume

0.4M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

Earnings

EPS

$0.00

EPS estimate (current quarter)

-$0.48

EPS estimate (next quarter)

-$0.57

EBITDA

$-125M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

52-week High

$29.98

52-week Low

$5.49

50-day moving average

$22.39

200-day moving average

$14.52

Short ratio

11.8

Short %

15.18%

Management effectiveness

ROE (TTM)

0.00%

ROA (TTM)

0.00%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

48.4M

Float

34.2M

Insiders %

2.96%

Institutions %

79.40%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 8 analysts.

Average price target

$45.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$1.91

-$0.40

-376.63%

Q3 • 24Missed

-$0.54

-$0.41

-31.71%

Q4 • 24Missed

-$0.50

-$0.48

-6.06%

Q1 • 25Missed

-$0.46

-$0.66

30.30%

Q2 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-21M

-∞%

Q1 • 25

$0M

$-24.6M

-∞%

Q2 • 25

NaN%

17.02%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$377M

$12.4M

3.28%

Q1 • 25

$357M

$13.8M

3.85%

Q2 • 25

-5.22%

11.21%

17.34%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-20.9M

$42.9M

$0M

$-20.9M

Q1 • 25

$-23.1M

$4.9M

$0.1M

$-23.2M

Q2 • 25

10.91%

-88.66%

∞%

11.00%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Oruka Therapeutics, Inc. share?

Oruka Therapeutics, Inc. shares are currently traded for undefined per share.

How many shares does Oruka Therapeutics, Inc. have?

Oruka Therapeutics, Inc. currently has 48.4M shares.

Does Oruka Therapeutics, Inc. pay dividends?

No, Oruka Therapeutics, Inc. doesn't pay dividends.

What is Oruka Therapeutics, Inc. 52 week high?

Oruka Therapeutics, Inc. 52 week high is $29.98.

What is Oruka Therapeutics, Inc. 52 week low?

Oruka Therapeutics, Inc. 52 week low is $5.49.

What is the 200-day moving average of Oruka Therapeutics, Inc.?

Oruka Therapeutics, Inc. 200-day moving average is $14.52.

Who is Oruka Therapeutics, Inc. CEO?

The CEO of Oruka Therapeutics, Inc. is Dr. Lawrence Otto Klein Ph.D..

How many employees Oruka Therapeutics, Inc. has?

Oruka Therapeutics, Inc. has 28 employees.

What is the market cap of Oruka Therapeutics, Inc.?

The market cap of Oruka Therapeutics, Inc. is $1.28B.

What is the P/E of Oruka Therapeutics, Inc.?

The current P/E of Oruka Therapeutics, Inc. is null.

What is the EPS of Oruka Therapeutics, Inc.?

The EPS of Oruka Therapeutics, Inc. is $0.00.

What is the PEG Ratio of Oruka Therapeutics, Inc.?

The PEG Ratio of Oruka Therapeutics, Inc. is null.

What do analysts say about Oruka Therapeutics, Inc.?

According to the analysts Oruka Therapeutics, Inc. is considered a buy.